BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22920639)

  • 1. Monoclonal gammopathy of undetermined significance: an update for nephrologists.
    Parry HM; Pratt G; Hutchison CA
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):291-6. PubMed ID: 22920639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice. Monoclonal gammopathy of undetermined significance.
    Bladé J
    N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
    [No Abstract]   [Full Text] [Related]  

  • 3. Light-chain MGUS: implications for clinical practice.
    van Rhee F
    Lancet; 2010 May; 375(9727):1670-1. PubMed ID: 20472153
    [No Abstract]   [Full Text] [Related]  

  • 4. [Spectrum of monoclonal gammopathies].
    Matuszkiewicz-Rowińska J; Wieliczko M
    Wiad Lek; 2017; 70(6 pt 2):1170-1174. PubMed ID: 29533907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
    Graziani MS; Merlini G
    Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.
    Espiño M; Medina S; Blanchard MJ; Villar LM
    Br J Haematol; 2014 Mar; 164(5):752-5. PubMed ID: 24261626
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis of monoclonal gammopathy of renal significance.
    Bridoux F; Leung N; Hutchison CA; Touchard G; Sethi S; Fermand JP; Picken MM; Herrera GA; Kastritis E; Merlini G; Roussel M; Fervenza FC; Dispenzieri A; Kyle RA; Nasr SH;
    Kidney Int; 2015 Apr; 87(4):698-711. PubMed ID: 25607108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrillary glomerulopathy secondary to light chain deposition disease in a patient with monoclonal gammopathy.
    Sundaram S; Mainali R; Norfolk ER; Shaw JH; Zhang PL
    Ann Clin Lab Sci; 2007; 37(4):370-4. PubMed ID: 18000296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
    Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
    Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
    Adam Z; Nedbálková M; Krejcí M; Pour L; Husek K; Veselý K; Cermáková Z; Krivanová A; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):240-6. PubMed ID: 20394211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free light-chains and renal disorders: when small is worse.
    Hutchison CA; Pratt G
    Lancet; 2010 Oct; 376(9748):1220; author reply 1221-2. PubMed ID: 20934588
    [No Abstract]   [Full Text] [Related]  

  • 15. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
    Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
    Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.
    Nambirajan A; Bhowmik D; Singh G; Agarwal SK; Dinda AK
    Transpl Int; 2015 Mar; 28(3):375-9. PubMed ID: 25441103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MGRS - monoclonal gammopathy of renal significance].
    Wieliczko M; Matuszkiewicz-Rowińska J
    Wiad Lek; 2017; 70(6 pt 2):1175-1178. PubMed ID: 29533908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria.
    Honkanen E; Pettersson T; Teppo AM
    Clin Nephrol; 1995 Jul; 44(1):22-7. PubMed ID: 7554529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benign monoclonal gammopathies].
    Sibilia J; Fermand JP
    Rev Prat; 1993 Feb; 43(3):289-92. PubMed ID: 8502957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.